At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02652 CF PHARMTECH
Closed 01-12 16:08:28
32.000
+0.600
+1.91%
High32.400
Low30.800
Vol144.50K
Open31.420
D1 Closing31.400
Amplitude5.10%
Mkt Cap13.18B
Tradable Cap9.67B
Total Shares411.98M
T/O4.57M
T/O Rate0.05%
Tradable Shares302.22M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CF Pharmtech Repurchases 15,000 Shares for HKD 485,360 in HKEX Disclosure
CF PHARMTECH (02652): Company's Leading Inhaled Nucleic Acid Drug Development Project Selected for Jiangsu Province's 2025 Major Sci-Tech Program "Innovative Biopharmaceuticals"
Changfeng Pharmaceutical Co., Ltd. was established on January 24, 2013. The company is primarily focused on the research and development, manufacturing, and commercialization of inhalation technologies and inhalation medicines for the treatment of respiratory diseases. It has built a comprehensive product portfolio that serves a broad patient population, covers multiple medical specialties, and addresses various therapeutic areas. During the track record period, the company obtained six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), and generated substantial sales revenue, demonstrating its strong capabilities in clinical development, manufacturing, regulatory affairs, and commercialization.